Pulmonary Arterial Hypertension Market to Accelerate Substantially During the Forecast Period 2032 | Key Companies – Complexa, Acceleron, Reata Pharma, Liquidia Technologies, PhaseBio, and Others

Delveinsight Business Research LLP
DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Pulmonary Arterial Hypertension market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market. 

Pulmonary Arterial Hypertension: An Overview

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension that is characterized by elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to right ventricular dysfunction and vessel obstruction.

The main purpose of the treatment of Pulmonary Arterial Hypertension is to improve the symptoms of patients and slow the rate of clinical deterioration. General measures, supportive therapy, pharmacological treatment, and Surgical Treatment are used for treating Pulmonary Arterial Hypertension (PAH). 

Pulmonary Arterial Hypertension Market Key Facts

Pulmonary Arterial Hypertension is a rare disorder found in 15 to 50 persons per million within the United States and Europe. Idiopathic, heritable, and anorexigen-induced PAH make up 52.6% of all PAH cases. Generally, PAH affects women aged between 30 and 60 years. However, it can occur in males and is often associated with worse clinical outcomes. 

According to DelveInsight’s analysis, females have a high prevalence of PAH as compared to males.

As per the study conducted by Kirson et.al. (2011), the prevalence of Pulmonary Arterial Hypertension was observed to be 109 per million individuals (PMI) among the population fewer than 65 years old. Prevalence of Pulmonary Arterial Hypertension was found to be 451 per million individuals (PMI) among age groups older than 65 years.

Pulmonary Arterial Hypertension Market

The Pulmonary Arterial Hypertension (PAH) market size is anticipated to increase during the study period owing to the increasing incident population of PAH patients in the 7MM. Extensive research and development activities of pharmaceutical companies, along with the expected launch of approved therapies will also fuel the growth of the market. 

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Pulmonary Arterial Hypertension market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Pulmonary Arterial Hypertension market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Pulmonary Arterial Hypertension Epidemiology

The epidemiology section covers insights into the historical and current Pulmonary Arterial Hypertension patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Pulmonary Arterial Hypertension Epidemiology Segmentation

Total Prevalent Patient Population of PAH

Sub-type Specific Prevalence of PAH

Gender-specific Prevalence of PAH

Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched in the market during the study period. The analysis covers Pulmonary Arterial Hypertension market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Pulmonary Arterial Hypertension Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market

Pulmonary Arterial Hypertension Therapeutics Analysis

The Pulmonary Arterial Hypertension Therapeutics market is expected to increase owing to the upcoming therapies for the treatment of PAH. 

Some of the key Companies in the Pulmonary Arterial Hypertension (PAH) Market include:

United Therapeutics Corp.

Arena Pharmaceuticals

Altavant Sciences

Acceleron Pharma

Reata Pharmaceuticals

Liquidia Technologies

PhaseBio Pharmaceuticals

Complexa

And many others.

Pulmonary Arterial Hypertension (PAH) Therapies covered in the report include:

CXA-10

Aurora-GT

Ralinepag

RVT-1201

Sotatercept 

PB1046 Injection

Bardoxolone methyl 

Inhaled dry powder treprostinil 

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Pulmonary Arterial Hypertension Competitive Intelligence Analysis

4. Pulmonary Arterial Hypertension Market Overview at a Glance

5. Pulmonary Arterial Hypertension Disease Background and Overview

6. Pulmonary Arterial Hypertension Patient Journey

7. Pulmonary Arterial Hypertension Epidemiology and Patient Population

8. Pulmonary Arterial Hypertension Treatment Algorithm, Current Treatment, and Medical Practices

9. Pulmonary Arterial Hypertension Unmet Needs

10. Key Endpoints of Pulmonary Arterial Hypertension Treatment

11. Pulmonary Arterial Hypertension Marketed Products

12. Pulmonary Arterial Hypertension Emerging Therapies

13. Pulmonary Arterial Hypertension Seven Major Market Analysis

14. Attribute Analysis

15. Pulmonary Arterial Hypertension Market Outlook (7 major markets)

16. Pulmonary Arterial Hypertension Access and Reimbursement Overview

17. KOL Views on the Pulmonary Arterial Hypertension Market.

18. Pulmonary Arterial Hypertension Market Drivers

19. Pulmonary Arterial Hypertension Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market

Other Latest Reports By DelveInsight

Emphysema Market

DelveInsight’s “Emphysema Market” report delivers an in-depth understanding of the Emphysema, historical and forecasted epidemiology as well as the Emphysema market size, share, and trends in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/